The Novartis Venture Fund is considering investing into a start up,Genedata, and must take into account the valuation analysis by boththe start up as well as Venture Valuation — an independent boutiqueorganization that specializes in valuing high growth potential startups.NVF uses the Venture Valuation inputs to determine how best tostructure the next round of financing for Genedata and the caserequires the reader to discuss and analyze pricing, further financingrequirements, and exit strategy for the fund.
Keywords
Valuation, Start-up, Venture Capital, Pharmaceuticals, Investment Strategy, Fund
Settings
Switzerland
July 1999
Available Languages
English
Related material
Teaching note
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.
Copyright Information
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
